focuses on APIs, formulations, and contract development & manufacturing (CDMO), especially in ARV and oncology Past cycles saw strong growth from ARV APIs, now gradually diversifying into non-ARV and CDMO High capex and R&D aim to build a more diversified earnings base. Risks include pricing pressure in ARVs, client concentration, and execution of new capacities.

#WatchOutFor#FundamentalViews#TechnicalViews#EquityResearch#Miscellaneous

746 likes·72 comments